Loading
companiesCompany
Mariana Oncology
Mariana Oncology designs small protein fragments that carry a radioactive isotope to tumours, starting with small cell lung cancer. Novartis bought the company in 2024 for 1 billion dollars up front.
Overview
Mariana Oncology, founded in 2021 in Watertown, Massachusetts by Atlas Venture, Access Biotechnology and RA Capital Management, built a fully integrated radiopharmaceutical platform combining peptide discovery, radiochemistry, in-house GMP manufacturing, isotope supply and formulations to extend product shelf life. Its portfolio of peptide-based radioligand therapies addresses a range of solid tumours; the lead candidate MC-339 is a radioligand therapy for small cell lung cancer that was expected to enter the clinic in 2024. The company closed a USD 175 million Series B in September 2023 co-led by Deep Track Capital and Forbion, and in May 2024 agreed to be acquired by Novartis for USD 1 billion upfront and up to USD 750 million in milestones. As a Novartis company it announced a USD 50 million expansion of radioligand R&D facilities in June 2025.
Headquarters
Watertown, MA, US
Funding
All startupsAcquiredAcquired by Novartis
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · USD 1 billion upfront plus up to USD 750 million in milestones | 2024 | $1B | marianaoncology.com |
| Series B | 2023 | $175M | marianaoncology.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Acquired
Website
Founded
2021
Notes
top- MC-339 target not stated on fetched pages. Series A not fetched and omitted.
Similar pages
- CompanyPheon Therapeutics
Shares Forbion, Atlas Venture.
- CompanyObsidian Therapeutics
Shares Atlas Venture, RA Capital Management.
- CompanyTriana Biomedicines
Shares Atlas Venture, RA Capital Management.
- CompanyAriceum Therapeutics
Shares Radioligand therapy (beta emitters), Small-cell lung cancer.
- TrialStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
- TrialStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Shares Novartis, Small-cell lung cancer.